FGF19 and cancer

Advances in Experimental Medicine and Biology

Volumn 728, Issue , 2012, Pages 183-194

  Lin, Benjamin C ^a   Desnoyers, Luc R ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1A6 ANTIBODY; BETA KLOTHO; BLOCKING ANTIBODY; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 4; RECEPTOR; UNCLASSIFIED DRUG; BETA KLOTHO PROTEIN, HUMAN; BETA-KLOTHO PROTEIN, HUMAN; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MEMBRANE PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CARCINOGENESIS; COLON CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; RECEPTOR BINDING; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; ENZYME SPECIFICITY; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

MUS;

ANIMALS; CELL LINE; FIBROBLAST GROWTH FACTORS; HUMANS; MEMBRANE PROTEINS; NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SUBSTRATE SPECIFICITY;

EID: 84859518082     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0887-1_12     Document Type: Article

References (60)

1. Omitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2:REVIEWS3005
2. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139-149
3. SleemanM, Fraser J, McDonaldM et al. Identification ofa new fibroblast growth factor receptor, FGFR5. Gene 2001; 271:171-182
4. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7:165-197
5. Desnoyers LR, Pai R, Ferrando RE et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27:85-97
6. Nicholes K, Guillet S, Tomlinson E et al. A mouse model ofhepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160:2295-2307
7. Pai R, Dunlap D, Qing J et al. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 2008; 68:5086-5095
8. Kurosu H, Choi M, Ogawa Y et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity ofFGF19 andFGF21. JBiolChem2007; 282:26687-26695
9. Lin BC, Wang M, Blackmore C et al. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007; 282:27277-27284
10. Nishimura T, Utsunomiya Y, Hoshikawa M et al. Structure and expression of a novel human FGF, FGF-19, expressedinthe fetalbrain. BiochimBiophysActa 1999; 1444:148-151
11. Xie MH, Holcomb I, Deuel B et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 11:729-735
12. Inagaki T, Choi M, Moschetta A et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2:217-225
13. Choi M, Moschetta A, Bookout AL et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12:1253-1255
14. Asada M, Shinomiya M, Suzuki M et al. Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochim Biophys Acta 2009; 1790:40-48
15. Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27:3417-3428
16. Harmer NJ, Pellegrini L, Chirgadze D et al. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 2004; 43:629-640
17. Zhang X, Ibrahimi OA, Olsen SK et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281:15694-15700
18. Kuro-o M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab 2008; 19:239-245
19. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120-6123
20. Wu X, Ge H, Lemon B et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad SciUSA2009; 106:14379-14384
21. Tomiyama K, Maeda R, Urakawa I et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci USA 2010; 107:1666-1671
22. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16:179-186
23. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009; 9:639-651
24. Fausto N. Mouse liver tumorigenesis: models, mechanisms and relevance to human disease. Semin Liver Dis 1999; 19:243-252
25. Spangenberg HC, Thimme R, Blum HE. Serum markers ofhepatocellular carcinoma. Semin Liver Dis 2006; 26:385-390
26. Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/ dephosphorylation ofbeta-catenin. Curr Opin Cell Biol 2005; 17:459-465
27. NelsonWJ,NusseR. Convergence ofWnt,beta-catenin, andcadherinpathways. Science2004; 303:1483-1487
28. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127:469-480
29. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000; 287:1606-1609
30. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-1851
31. Morin PJ. beta-catenin signaling and cancer. Bioessays 1999; 21:1021-1030
32. WuX, Ge H, Lemon B et al. FGF19-inducedhepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 285:5165-5170
33. Ho HK, Pok S, Streit S et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 50:118-127
34. YuC, Wang F, JinC etal. Increased carbontetrachloride-induced liver injury and fibrosis inFGFR4-deficient mice. Am J Pathol 2002; 161:2003-2010
35. Huang X, Yang C, Jin C et al. Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog 2009; 48:553-562
36. Jaakkola S, Salmikangas P, Nylund S et al. Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 1993; 54:378-382
37. Roidl A, Berger HJ, Kumar S et al. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009; 15:2058-2066
38. Bange J, Prechtl D, Cheburkin Y et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62:840-847
39. Roidl A, Foo P, Wong W et al. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene 2010; 29:1543-1552
40. Spinola M, Leoni V, Pignatiello C et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005; 23:7307-7311
41. Ma Z, Tsuchiya N, Yuasa T et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008; 123:2574-2579
42. Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004; 10:6169-6178
43. Wang J,Yu W, CaiY et al. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008; 10:847-856
44. Falvella FS, Frullanti E, Galvan A et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage ofpatients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer 2009; 124:2880-2885
45. Sasaki H, Okuda K, Kawano O et al. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer. Oncol Rep 2008; 20:1125-1130
46. Ansell A, Farnebo L, Grenman R et al. Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol 2009; 45:23-29
47. da Costa Andrade VC, Parise O, Jr., Hors CP et al. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007; 82:53-57
48. Streit S, Bange J, Fichtner A et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004; 111:213-217
49. Streit S, Mestel DS, Schmidt M et al. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006; 94:1879-1886
50. Morimoto Y, Ozaki T, Ouchida M et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003; 98:2245-2250
51. Jezequel P, Campion L, Joalland MP et al. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004; 90:189-193
52. Mawrin C, Kirches E, Diete S et al. Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas. Cancer Lett 2006; 239:239-245
53. Yang YC, Lu ML, Rao JY et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. BrJ Cancer 2006;95:1455-1458
54. Matakidou A, El Galta R, Rudd MF et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007; 96:1904-1907
55. Nan H, Qureshi AA, Hunter DJ et al. Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses Health Study. BMC Cancer 2009; 9:172
56. Liu H, Fergusson MM, Castilho RM et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317:803-806
57. Engstrom W, Granerus M. Effects of fibroblast growth factors 19 and 20 on cell multiplication and locomotion in a human embryonal carcinoma cell line (Tera-2) in vitro. Anticancer Res 2006; 26:3307-3310
58. Miyake A, Nakayama Y, Konishi M et al. Fgf19 regulated by Hh signaling is required for zebrafish forebrain development. Dev Biol 2005; 288:259-275
59. Siffroi-Fernandez S, Felder-Schmittbuhl MP, Khanna H et al. FGF19 exhibits neuroprotective effects on adult mammalian photoreceptors in vitro. Invest Ophthalmol Vis Sci 2008; 49:1696-1704
60. Thussbas C, Nahrig J, Streit S et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006;24:3747-3755